Prevalence and Risk Factors of Bisphosphonate-Associated Osteonecrosis of the Jaw in Prostate Cancer Patients with Advanced Disease Treated with Zoledronate

Walter, Christian; Al‐Nawas, Bilal; Grötz, K. A.; Thomas, Christian; Thüroff, Joachim W.; Zinser, Viktoria; Gamm, H.; Beck, Joachim; Wagner, Wilfried

doi:10.1016/j.eururo.2008.06.070

Cited by 153 publications

(120 citation statements)

References 30 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…BRONJ prevalence in cancer patients (range 3-18%) has been the focus of the majority of papers [3,55] to date, whereas the impact of BRONJ in non-cancer patients, with osteoporosis or Paget disease, who receive lower doses of BPs is less known [34,37]. The estimated prevalence of BRONJ in non-cancer (mainly osteoporotic) patients may range from 0.02% to 11% [22][23][24]29,33,36,42,44,47,49].…”

Section: European Journal Of Internal Medicine 24 (2013) 784-790mentioning

confidence: 99%

Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: A retrospective multi-hospital-based study of 87 Italian cases

Fede

Fusco

Matranga

et al. 2013

European Journal of Internal Medicine

View full text Add to dashboard Cite

Section: European Journal Of Internal Medicine 24 (2013) 784-790mentioning

confidence: 99%

Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: A retrospective multi-hospital-based study of 87 Italian cases

Fede

Fusco

Matranga

et al. 2013

European Journal of Internal Medicine

View full text Add to dashboard Cite

“…In most BP-ONJ case series and case reports, the authors report a previous dental surgical procedure. 7,16 Therefore, guidelines have been established that recommend introducing patients to a dentist or an oral and maxillofacial surgeon before bisphosphonate therapy starts, with the goal of restoring and/ or extracting teeth before treatment. This regimen is already routinely practice for patients with forthcoming radiation.…”

mentioning

confidence: 99%

Incidence of bisphosphonate‐associated osteonecrosis of the jaws in breast cancer patients

Walter

Al‐Nawas

Bois

et al. 2009

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUND:Bisphosphonate‐associated osteonecrosis of the jaws (BP‐ONJ) is a relatively new disease. The aim of this study was to evaluate the prevalence of BP‐ONJ in breast cancer patients with osseous metastasis and bisphosphonate therapy.METHODS:A retrospective study was conducted in a EUSOMA accredited breast unit in Germany. All patients treated from January of 2000 to March of 2006 with metastatic breast cancer and bisphosphonate therapy were reviewed. All patients were contacted, and missing data were completed through structured interviews with their dentists and physicians (n = 75). Primary outcome was the development of BP‐ONJ and the detection of possible additional trigger factors for the development of BP‐ONJ.RESULTS:A total of 117 patients with breast cancer fulfilled the inclusion criteria, and data for 75 still living patients were included. Of these 75, 4 patients developed a BP‐ONJ, resulting in a prevalence of 5.3%: 3 patients received zoledronate only; 1 patient had first pamidronate followed by zoledronate and ibandronate. A tooth extraction could be identified as an additional trigger factor for 2 patients.CONCLUSIONS:With a prevalence of 5.3%, BP‐ONJ in breast cancer patients has become a relevant disease that should be discussed with patients for whom bisphosphonates have been recommended. Appropriate dental care before bisphosphonate therapy commences has been advised to reduce the occurrence of BP‐ONJ. Cancer 2009. © 2009 American Cancer Society.

show abstract

“…[19][20][21][22][23][24] BRONJ usually occurs more frequently in patients receiving nitrogen-containing bisphosphonates via parenteral route than oral administration. [24][25][26][27] Researchers reported the incidence of BRONJ after oral surgery (like tooth extraction) with cancer patients receiving intravenous bisphosphonates between 6.5% and 51.8%. [28][29][30] Historically, the risk of developing osteonecrosis (at any site) is four times higher in cancer patients than in the normal population and has multiple risk factors, including previous/ concomitant chemotherapy, regular steroid therapy, immunosuppressant therapy, radiation therapy, diabetes, hypertension, obesity, certain gene mutations, tobacco habit, alcoholism 19,[24][25][26][27] as well as poor oral hygiene, chronic oral trauma, previously existing local infection and a history of dental procedures.…”

Section: Discussionmentioning

confidence: 99%

“…[28][29][30] Historically, the risk of developing osteonecrosis (at any site) is four times higher in cancer patients than in the normal population and has multiple risk factors, including previous/ concomitant chemotherapy, regular steroid therapy, immunosuppressant therapy, radiation therapy, diabetes, hypertension, obesity, certain gene mutations, tobacco habit, alcoholism 19,[24][25][26][27] as well as poor oral hygiene, chronic oral trauma, previously existing local infection and a history of dental procedures. [25][26][27]31,32 Zoledronic acid is known to be more potent than all the other bisphosphonates and it is reported that patients taking zoledronic acid are 30 times more likely to develop osteonecrosis. 25 The patient had not used cigarette and alcohol.…”

Section: Discussionmentioning

confidence: 99%

Malnutrition due to bisphosphonate-related osteonecrosis of the jaw in a chronic dialysis patient: case report

Akar

Efeoğlu

Alp³

et al. 2013

Renal Failure

View full text Add to dashboard Cite

Adequate nutrition is imperative for a successful outcome in dialysis patients. Excellent oral hygiene and an efficient mastication can help to correct several metabolic and endocrine disturbances as well as delay initiation of dialysis in patients with chronic renal failure. However, concerns exist about the risk of malnutrition and protein depletion. On the other hand, intravenous bisphosphonates are the current standard of care for the treatment of hypercalcemia of malignancy and for the prevention of skeletal complications associated with bone metastases. Recently, retrospective case studies have reported an association between long-term bisphosphonate therapy and osteonecrosis of the jaws. This complication occurs either spontaneously or after minor dento-alveolar surgery including extraction of teeth. A malnourished dialysis patient who showed the typical clinical features of bisphosphonaterelated osteonecrosis of the jaw (BRONJ) without any obvious radiological changes in his panoramic radiograph is reported. To minimize the risk of BRONJ, patients initiated on bisphosphonates should optimize routine dental care and have their baseline oral health evaluated by both clinical and radiographic examinations before initiation of bisphosphonate therapy.

show abstract

Prevalence and Risk Factors of Bisphosphonate-Associated Osteonecrosis of the Jaw in Prostate Cancer Patients with Advanced Disease Treated with Zoledronate

Cited by 153 publications

References 30 publications

Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: A retrospective multi-hospital-based study of 87 Italian cases

Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: A retrospective multi-hospital-based study of 87 Italian cases

Incidence of bisphosphonate‐associated osteonecrosis of the jaws in breast cancer patients

Malnutrition due to bisphosphonate-related osteonecrosis of the jaw in a chronic dialysis patient: case report

Contact Info

Product

Resources

About